Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 11/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122447 | 0.88 | KDM5A (0.53) | MAPTTP53KDM5APOLBGAA | |
| SCHEMBL2122557 | 0.86 | MAPT (0.45) | MAPTTP53KDM5APOLBGAA | |
| SCHEMBL2124746 | 0.86 | KDM5A (0.52) | MAPTTP53KDM5AGAA | |
| SCHEMBL2124502 | 0.85 | KDM5A (0.53) | MAPTTP53KDM5APOLBGAA | |
| SCHEMBL2124763 | 0.84 | KDM5A (0.47) | MAPTTP53KDM5APOLBGAA | |
| SCHEMBL2124113 | 0.84 | KDM5A (0.46) | MAPTTP53KDM5A | |
| SCHEMBL2125875 | 0.84 | KDM5A (0.47) | MAPTTP53KDM5APOLBGAA | |
| SCHEMBL2125644 | 0.83 | MAPT (0.48) | MAPTTP53KDM5APOLB | |
| SCHEMBL2126373 | 0.83 | MAPT (0.52) | MAPTTP53KDM5APOLB | |
| SCHEMBL2123179 | 0.83 | KDM5A (0.58) | MAPTTP53KDM5APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | MAPT 4045/4885TP53 639/4885KDM5A 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.